公开(公告)号：US20230002394A1

公开(公告)日：2023-01-05

申请号：US17724138

申请日：2022-04-19

申请人： AKARNA THERAPEUTICS, LTD.

发明人： Raju Mohan ,  Benjamin Anthony Pratt

IPC分类号： C07D487/04 ,  C07D471/04 ,  A61P9/10 ,  A61P1/16 ,  A61P3/00 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10 ,  C07D471/14

摘要： Described herein are fused bicyclic compounds, compositions, and methods for their use for the treatment of disease.

公开(公告)号：US11541025B2

公开(公告)日：2023-01-03

申请号：US16603301

申请日：2018-04-03

申请人： SOCIETE DES PRODUITS NESTLE S.A.

发明人： Rachid Bel-Rhlid

IPC分类号： A61K31/192 ,  A23L33/195 ,  A23L7/10 ,  A23L33/105 ,  A61P3/04 ,  A61P3/10 ,  A61K9/00

摘要： The present invention relates to a method of preparing a composition comprising ferulic acid. An aspect of the invention is a composition comprising hydrolysed wheat bran for use in the treatment or prevention of metabolic disease.

公开(公告)号：US20220389431A1

公开(公告)日：2022-12-08

申请号：US17761975

申请日：2020-09-25

申请人： Brown University

发明人： Elena OANCEA

IPC分类号： C12N15/113 ,  A61P3/04

摘要： Described herein are methods and compositions for the prevention or treatment of obesity and obesity-related disorders. The methods and compositions are based, inter alia, on the observations that OPN3 is the most highly expressed opsin in the hypothalamus, a key site for the regulation of energy homeostasis. Indeed, OPN3 expression was highest in regions associated with energy homeostasis, namely the paraventricular nucleus and arcuate nucleus of the hypothalamus. OPN3 was shown to interact and form a complex with MC3R and MC4R, and to modulate MC3R- and MC4R-mediated signaling in the hypothalamus. Accordingly, the methods involve the regulation of melanocortin receptors by downregulating opsin 3 (OPN3) protein expression, OPN3 gene expression, and/or OPN3 activation in the hypothalamus.

公开(公告)号：US20220387307A1

公开(公告)日：2022-12-08

申请号：US17479780

申请日：2021-09-20

申请人： Thomas M. Crews

发明人： Thomas M. Crews

IPC分类号： A61K9/00 ,  A61K45/06 ,  A61K9/08 ,  A61K31/439 ,  A61K31/245 ,  A61K31/4152 ,  A61K31/167 ,  A61P11/06 ,  A61P3/04 ,  A61P1/00 ,  A61P11/00 ,  A61P29/00 ,  A61P1/04 ,  A61K31/047 ,  A61K31/137 ,  A61K31/445 ,  A61K31/47

摘要： The present disclosure relates to methods for treating a variety of diseases and/or ameliorating pain by administering to the ear canal of a subject a composition.

公开(公告)号：US20220386675A1

公开(公告)日：2022-12-08

申请号：US17775889

申请日：2020-12-04

申请人： N.V. Nutricia

发明人： Stefanie Schoen ,  Dennis Stanley Acton

IPC分类号： A23L33/00 ,  A23L33/12 ,  A23L33/17 ,  A61P3/04

摘要： The present invention relates to formulae for infants born via Caesarean section for improving the postnatal growth trajectory or body development.

公开(公告)号：US20220378743A1

公开(公告)日：2022-12-01

申请号：US17435061

申请日：2020-02-26

申请人： BEIJING TIDE PHARMACEUTICAL CO., LTD.

发明人： Yuanyuan JIANG ,  Weiting ZHONG ,  Yanping ZHAO ,  Hongjun WANG ,  Jing ZHAO ,  Jing Li ,  Weina LIU ,  Liying ZHOU ,  Yanan LIU

IPC分类号： A61K31/416 ,  A61K31/343 ,  A61K9/06 ,  A61K9/08 ,  A61P3/04

摘要： The present invention falls within the field of biological medicine, and specifically relates to a method for preventing, alleviating and/or treating fatty liver disease and/or steatohepatitis. The method comprises administering, to an individual in need thereof, an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, an ester, a stereoisomer, a polymorph, a solvate, an N-oxide, an isotopically labeled compound, a metabolite or a prodrug thereof.

公开(公告)号：US20220378737A1

公开(公告)日：2022-12-01

申请号：US17873638

申请日：2022-07-26

申请人： Boehringer Ingelheim Vetmedica GmbH

发明人： Saskia KLEY ,  Dania REICHE

IPC分类号： A61K31/351 ,  A61K38/28 ,  A61K9/20 ,  A61K9/48 ,  A61K9/02 ,  A61K31/7034 ,  A61K45/06 ,  A61K9/08 ,  A61K31/00 ,  C07D309/10 ,  A61P5/50 ,  A61P27/12 ,  A61K47/22 ,  A61K31/352 ,  A61P9/12 ,  A61K9/14 ,  A61P3/00 ,  A61P3/06 ,  C07D493/08 ,  A61P3/10 ,  A61P3/04 ,  A61P31/12 ,  A61P29/00 ,  A61K9/00 ,  A61K31/401

摘要： One or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof are provided for use in the treatment and/or prevention of a metabolic disorder in a canine animal, preferably where the metabolic disorder is one or more selected from ketoacidosis, pre-diabetes, insulin dependent diabetes mellitus, insulin resistance diabetes, insulin resistance, obesity, hyperglycemia, hyperglycemia induced cataract formation, impaired glucose tolerance, hyperinsulinemia, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, hepatic lipidosis, inflammation of the pancreas, metabolic disorder consequences, such as hypertension, renal dysfunction and/or musculoskeletal disorders, and/or Syndrome X (metabolic syndrome), wherein preferably the development of hyperglycemia induced cataract formation is prevented or remission is achieved and/or wherein preferably the development of metabolic disorder consequences, such as hypertension, renal dysfunction and/or musculoskeletal disorders, is prevented or progression is slowed or remission is achieved.

公开(公告)号：US20220362178A1

公开(公告)日：2022-11-17

申请号：US17861054

申请日：2022-07-08

申请人： DIET SHIELD LTD

发明人： Andrew KITCHNER ,  Denis CARR

IPC分类号： A61K31/164 ,  A61K9/00 ,  A61K31/16 ,  A61K47/44 ,  A61K31/165 ,  A61K47/10 ,  A61P25/34 ,  A61P3/04

摘要： Provided are compositions and methods comprising a sanshool for the treatment of obesity as part of a controlled diet regime in an individual. Also provided are compositions and methods comprising a sanshool for treatment of a smoking or vaping addiction. Suitably the compositions are applied topically to the lips of the individual in response to a habitual urge to consume food, smoke or vape as required.

公开(公告)号：US20220347238A1

公开(公告)日：2022-11-03

申请号：US17378955

申请日：2021-07-19

申请人： GLAC BIOTECH CO., LTD

发明人： Chi-Chang HUANG ,  Mon-Chien LEE ,  Yi-Ju HSU ,  Hsieh-Hsun HO ,  Yi-Wei KUO ,  Wen-Yang LIN ,  Jia-Hung LIN ,  Chi-Huei LIN

IPC分类号： A61K35/747 ,  A61P3/04 ,  A61K35/745 ,  A23L33/135 ,  C12N1/20

摘要： The present invention provides a lactic acid bacteria composition, which comprises: a Lactobacillus plantarum PL-02 strain, a Lactobacillus acidophilusTYCA06 strain, a Lactobacillus casei CS-773 strain, and a physiologically acceptable excipient, diluent, or carrier. All of the strains are deposited at the

公开(公告)号：US11485766B2

公开(公告)日：2022-11-01

申请号：US17134982

申请日：2020-12-28

申请人： Sun Pharmaceutical Industries Limited

发明人： Rajamannar Thennati ,  Nishith Chaturvedi ,  Vinod Sampatrao Burade ,  Pradeep Dinesh Shahi ,  Muthukumaran Natarajan ,  Ravishankara Madavati Nagaraja ,  Rishit Mansukhlal Zalawadia ,  Vipulkumar Shankarbhai Patel ,  Kunal Pandya ,  Brijeshkumar Patel ,  Dhiren Rameshchandra Joshi ,  Krunal Harishbhai Soni ,  Abhishek Tiwari

IPC分类号： C07K14/605 ,  A61K9/00 ,  A61P3/10 ,  A61P3/04 ,  A61K38/00

摘要： The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.